NASDAQ$DVAX
Dynavax Technologies Corp · Q4 2019 earnings
Q4 2019 earnings · · Investor relations
Briefing
Dynavax reported financial results for the fourth quarter and full year 2019.
Dynavax's Q4 2019 earnings show a net product revenue of $10.6 million, a significant increase from $3.9 million in Q4 2018. The company's market share in targeted accounts also rose to 21% from 18% in the previous quarter. The net loss allocable to common stockholders was $36.8 million, or $0.44 per share.
- HEPLISAV-B net product revenue for Q4 2019 was $10.6 million, up from $3.9 million in Q4 2018.
- Market share in accounts targeted by the field sales team increased to 21% in Q4 2019 from 18% in Q3 2019.
- Net loss allocable to common stockholders for Q4 2019 was $36.8 million, or $0.44 per basic and diluted share.
- Cash, cash equivalents and marketable securities totaled $151.1 million at December 31, 2019.
Headline financials
Revenue & EPS history
Dynavax · Revenue · Quarterly
$10.6M
Revenue by segment
Dynavax · $10.6M total across 2 segments · Q4 2019
- HEPLISAV-B Net Product Revenue$10.6M+168.5%99.9%
- Other Revenue$12K—0.1%
Forward guidance
Dynavax anticipates HEPLISAV-B® net product revenue to increase to $55-$62 million for the full year 2020. They plan to release interim data from an ongoing study of HEPLISAV-B in patients on hemodialysis in Q1 2020 and final immunogenicity data in the second half of 2020. They also aim to complete safety follow-up for HEPLISAV-B post-marketing studies in Q4 2020.
Tailwinds
- HEPLISAV-B® net product revenue expected to increase to $55-$62 million for the full year 2020
- Release interim data from ongoing study of HEPLISAV-B in patients on hemodialysis in Q1 2020 and final immunogenicity data in the second half of 2020
- Complete Phase 1-enabling animal studies and toxicology for improved pertussis vaccine with CpG 1018
- Enter multiple strategic relationships focused on initial research in a variety of vaccine candidates to establish CpG 1018 as a leading adjuvant
- Complete safety follow-up for HEPLISAV-B post-marketing studies in Q4 2020
Headwinds
- The vaccine market and/or the adult hepatitis B market may not grow as expected
- HEPLISAV-B may not provide the anticipated benefits and may not become the standard of care adult hepatitis B vaccine in the U.S.
- Dynavax's growth initiatives may not be successful
- The company's 2020 revenue and/or expenses may not meet expectations
- The adverse effects of the recent coronavirus pandemic on our ability to access customers and on customer decision making, adoption and implementation
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 16 quarterly earnings reports
-0.6%
Avg return
Earnings day
+1.2%
Avg return
5 days after
+0.9%
Avg return
30 days after
49%
31 / 63 earnings
Positive
+18.1%
Q1 2019
Best reaction
-29.1%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | -1.5% | +2.4% | -1.0% | |
| Q2 2025 | -6.7% | -2.2% | -9.0% | |
| Q1 2025 | -11.0% | -9.6% | -6.1% | |
| Q4 2024 | +0.0% | +2.5% | +3.6% | |
| Q3 2024 | +5.9% | +9.6% | +4.5% | |
| Q2 2024 | +6.8% | +10.1% | +7.2% | |
| Q1 2024 | -6.4% | -6.2% | +2.6% | |
| Q4 2023 | +2.3% | +4.3% | -1.4% | |
| Q3 2023 | +0.9% | -5.5% | -2.8% | |
| Q2 2023 | +7.1% | +10.0% | +7.4% | |
| Q1 2023 | +4.8% | +7.0% | +9.0% | |
| Q4 2022 | -5.0% | -5.5% | -9.4% | |
| Q3 2022 | +11.6% | +10.3% | +12.6% | |
| Q2 2022 | +17.8% | +20.7% | -20.6% | |
| Q1 2022 | -4.3% | -12.0% | +29.7% | |
| Q4 2021 | -2.2% | -16.1% | -11.8% | |
| Q3 2021 | -22.8% | — | — | |
| Q2 2021 | +6.1% | — | — | |
| Q1 2021 | +9.7% | — | — | |
| Q4 2020 | -6.7% | — | — | |
| Q3 2020 | +0.5% | — | — | |
| Q2 2020 | -13.5% | — | — | |
| Q1 2020 | -8.8% | — | — | |
| Q4 2019 | -29.1% | — | — | |
| Q3 2019 | -5.4% | — | — | |
| Q2 2019 | +5.2% | — | — | |
| Q1 2019 | +18.1% | — | — | |
| Q4 2018 | -7.8% | — | — | |
| Q3 2018 | +2.2% | — | — | |
| Q2 2018 | +5.8% | — | — | |
| Q1 2018 | -5.0% | — | — | |
| Q4 2017 | -0.3% | — | — | |
| Q3 2017 | +6.4% | — | — | |
| Q2 2017 | +12.7% | — | — | |
| Q1 2017 | +0.9% | — | — | |
| Q4 2016 | -2.5% | — | — | |
| Q3 2016 | +6.7% | — | — | |
| Q2 2016 | -2.3% | — | — | |
| Q1 2016 | +8.7% | — | — | |
| Q4 2015 | -4.6% | — | — | |
| Q3 2015 | -1.5% | — | — | |
| Q2 2015 | +10.8% | — | — | |
| Q1 2015 | +1.9% | — | — | |
| Q4 2014 | +0.1% | — | — | |
| Q3 2014 | -1.9% | — | — | |
| Q2 2014 | -9.2% | — | — | |
| Q1 2014 | -3.9% | — | — | |
| Q4 2013 | -4.2% | — | — | |
| Q3 2013 | +4.5% | — | — | |
| Q2 2013 | +2.4% | — | — | |
| Q1 2013 | -5.2% | — | — | |
| Q4 2012 | +2.1% | — | — | |
| Q3 2012 | +0.5% | — | — | |
| Q2 2012 | +2.4% | — | — | |
| Q1 2012 | -3.6% | — | — | |
| Q4 2011 | +3.1% | — | — | |
| Q3 2011 | -14.0% | — | — | |
| Q2 2011 | -14.6% | — | — | |
| Q1 2011 | -1.1% | — | — | |
| Q4 2010 | -2.5% | — | — | |
| Q3 2010 | +2.4% | — | — | |
| Q2 2010 | -8.1% | — | — | |
| Q1 2010 | +7.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro